Literature DB >> 6233935

Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

A L Barry, R N Jones, C Thornsberry, L W Ayers, E H Gerlach, H M Sommers.   

Abstract

In vitro studies were performed comparing ciprofloxacin (Bay o 9867) and norfloxacin with three related organic acids. Ciprofloxacin was two to eight times more active than norfloxacin against 658 bacterial isolates representing 30 species. For all species tested, ciprofloxacin MICs for 90% inhibition were less than or equal to 2.0 micrograms ml. Additional tests with 5,994 isolates detected only 37 (0.6%) strains resistant to 2.0 micrograms of ciprofloxacin per ml and 106 (1.8%) resistant to 1.0 micrograms/ml. Only 6 (0.1%) of the 5,994 strains were resistant to 16 micrograms of norfloxacin per ml, and 129 (2.1%) were resistant to 4.0 micrograms/ml. The majority of resistant strains were streptococci or Pseudomonas spp. Resistance among the Enterobacteriaceae was extremely rare (i.e., greater than 99.8% susceptible to both drugs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6233935      PMCID: PMC185603          DOI: 10.1128/AAC.25.5.633

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

2.  Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.

Authors:  R N Jones; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1983-06       Impact factor: 2.803

3.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

4.  Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715).

Authors:  D L Shungu; E Weinberg; H H Gadebusch
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

5.  Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.

Authors:  H L Muytjens; J van der Ros-van de Repe; G van Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

6.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

7.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

8.  In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

  8 in total
  74 in total

1.  Ciprofloxacin concentration in the rabbit aqueous humor and vitreous following intravenous and subconjunctival administration.

Authors:  W Behrens-Baumann; J Martell
Journal:  Infection       Date:  1988       Impact factor: 3.553

2.  Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men.

Authors:  R E Roddy; H H Handsfield; E W Hook
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

3.  In vitro activity of Ro 24-6392, a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.

Authors:  R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

4.  In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.

Authors:  J M Stamm; C W Hanson; D T Chu; R Bailer; C Vojtko; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

5.  [Dependence of the bactericidal activity and mutant selection of 4-quinolones on their serum concentration levels].

Authors:  A Bauernfeind; C Petermüller; B Heinrich; R Gablac
Journal:  Infection       Date:  1986       Impact factor: 3.553

6.  In vitro susceptibility of Neisseria gonorrhoeae to RO 23-6240 and ciprofloxacin.

Authors:  S S Kaukoranta-Tolvanen; O V Renkonen
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

7.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

8.  Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia.

Authors:  P Saux; C Martin; M N Mallet; L Papazian; B Bruguerolle; P De Micco; F Gouin
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  Inappropriate breast secretions of possible bacterial etiology in the parous nonpuerperal female.

Authors:  J J Freeman; R H Altieri; A H Freeman; T Kuo; F Sardinha; C C Buckingham; J J Sklar; K Dyroff; A Floyd
Journal:  J Natl Med Assoc       Date:  1994-03       Impact factor: 1.798

Review 10.  Current problems of chemotherapy of infections with coagulase-negative staphylococci.

Authors:  A J Davies; J W Stone
Journal:  Eur J Clin Microbiol       Date:  1986-06       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.